Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | EYA2 | O00167 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.30 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19069557 | 0.78 | TDP1 (0.33) | TDP1EYA2APPACEADRA1A | |
| SCHEMBL30987828 | 0.75 | ALDH1A1 (0.31) | TDP1EYA2APPACEADRA1A | |
| SCHEMBL25547871 | 0.75 | ADRA2A (0.32) | TDP1EYA2APPACEADRA1A | |
| SCHEMBL20811652 | 0.70 | ALDH1A1 (0.32) | TSHR | |
| SCHEMBL26821507 | 0.68 | TDP1 (0.52) | TDP1EYA2APPACEADRA1A | |
| SCHEMBL29230313 | 0.67 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL29230314 | 0.67 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL3440469 | 0.67 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL9611561 | 0.67 | FDPS (0.34) | TDP1ADRA1ACHRM1ADRA2ADRD3 | |
| SCHEMBL755837 | 0.67 | FDPS (0.34) | TDP1ADRA1ACHRM1ADRA2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119365471-A | Novel thiol reducing agents, methods and uses thereof | 苏州佰睿壹生物技术有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-2864457-B1 | FRICTION MODIFIER AND THEIR USE IN LUBRICANTS AND FUELS | CASTROL LTD (GB) | 2017-08-16 | — | — | EP | disclosed |
| US-9217117-B2 | Friction modifier and their use in lubricants and fuels | CASTROL LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-20150218479-A1 | FRICTION MODIFIER AND THEIR USE IN LUBRICANTS AND FUELS | CASTROL LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| EP-2864457-A1 | FRICTION MODIFIER AND THEIR USE IN LUBRICANTS AND FUELS | Castrol Limited (GB) | 2015-04-29 | — | — | EP | disclosed |
| WO-2013189675-A1 | FRICTION MODIFIER AND THEIR USE IN LUBRICANTS AND FUELS | CASTROL LIMITED (GB) | 2013-12-27 | — | — | WO | disclosed |
| EP-1694329-A4 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES | ATON PHARMA INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | ATON PHARMA, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1694329-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES | Aton Pharma, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005053610-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6759509-B1 | CONJUGATES CONTAINING A TARGETING LIGAND, SUCH AS AN ANTIBODY, A THERAPEUTICALLY ACTIVE DRUG AND A BRANCHED PEPTIDE LINKER | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023718-A1 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives | AADAC, BRDT, HDAC5 | TDP1 1170/4885EYA2 939/4885APP 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.